

Review

Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling

Jing Pan *, Rakeshwar S. Guleria, Sen Zhu and Kenneth M. Baker

Division of Molecular Cardiology, Department of Medicine, College of Medicine, Texas A & M Health Science Center, Baylor Scott & White Health, Central Texas Veterans Health Care System, Temple, TX, 76504, USA; E-Mails: rsguleria@medicine.tamhsc.edu (R.S.G.); szhu@medicine.tamhsc.edu (S.Z.); kbaker@medicine.tamhsc.edu (K.M.B.)

* Author to whom correspondence should be addressed; E-Mail: jpan@medicine.tamhsc.edu; Tel.: +1-254-743-2461; Fax: +1-254-743-0165.

Received: 19 February 2014; in revised form: 17 March 2014 / Accepted: 25 March 2014 /

Published: 4 June 2014

Abstract: Diabetic cardiomyopathy (DCM), a significant contributor to morbidity and mortality in diabetic patients, is characterized by ventricular dysfunction, in the absence of coronary atherosclerosis and hypertension. There is no specific therapeutic strategy to effectively treat patients with DCM, due to a lack of a mechanistic understanding of the disease process. Retinoic acid, the active metabolite of vitamin A, is involved in a wide range of biological processes, through binding and activation of nuclear receptors: retinoic acid receptors (RAR) and retinoid X receptors (RXR). RAR/RXR-mediated signaling has been implicated in the regulation of glucose and lipid metabolism. Recently, it has been reported that activation of RAR/RXR has an important role in preventing the development of diabetic cardiomyopathy, through improving cardiac insulin resistance, inhibition of intracellular oxidative stress, NF- κ B-mediated inflammatory responses and the renin-angiotensin system. Moreover, downregulated RAR/RXR signaling has been demonstrated in diabetic myocardium, suggesting that impaired RAR/RXR signaling may be a trigger to accelerate diabetes-induced development of DCM. Understanding the molecular mechanisms of retinoid receptors in the regulation of cardiac metabolism and remodeling under diabetic conditions is important in providing the impetus for generating novel therapeutic approaches for the prevention and treatment of diabetes-induced cardiac complications and heart failure.

Keywords: diabetes mellitus; diabetic cardiomyopathy; retinoic acid; retinoic acid receptor; retinoid X receptor

1. Introduction

Diabetic cardiomyopathy (DCM), characterized by alterations in cardiac morphology and function, independent of hypertension or coronary disease, is a significant contributor to morbidity and mortality associated with diabetes [1,2]. The etiology of DCM is multifactorial and incompletely understood. We and others have shown that chronically activated cardiac NF- κ B, JNK pathways, impaired insulin signaling-induced metabolic disturbances, dysregulated calcium homeostasis and an over-activated renin-angiotensin system are emerging as major molecular and metabolic mechanisms for DCM [3–8]. There is no specific therapeutic strategy to effectively treat patients with DCM, due to a lack of mechanistic details.


Retinoic acids (RA), the active metabolite of retinol (vitamin A), are involved in the regulation of cell proliferation and differentiation, with effects being mediated by two classes of nuclear receptors, retinoic acid receptors (RAR) and retinoid X receptors (RXR). Retinoic acid signaling components (retinol binding protein 4, retinal, retinoic acid and retinoid receptors) have been implicated in modulating the development of obesity, insulin resistance and diabetes [9–15]. Whether retinoic acid and RAR/RXR-mediated signaling are of importance in the development of DCM is not well known. This review will focus on recent new developments in retinoic acid signaling and diabetes-induced cardiac remodeling.

2. Diabetic Cardiomyopathy

The epidemic of obesity and a sedentary lifestyle is projected to result in over 439 million individuals with diabetes mellitus (DM) worldwide by 2030 [16]. DM is an important and prevalent risk factor for congestive heart failure. Indeed, cardiovascular complications are the leading cause of diabetes-related morbidity and mortality (65%) [17]. Heart failure (HF) is a syndrome that represents the end stage of different forms of heart disease, affecting nearly 5.8 million people in the United States, and more than 23 million people worldwide [18]. HF results in high hospitalization rates and mortality; up to 40% of patients die within one year of their first hospitalization, resulting in significant health and financial burdens on patients and society [19,20]. The Framingham report indicates that diabetes increases the risk of heart failure, independent of other contributing risk factors [21,22]. The risk of heart failure in diabetic subjects was increased 2.4-fold in men and five-fold in women. This risk was independent of age, hypertension, obesity, coronary artery disease and hyperlipidemia. The impairment of left ventricular function in diabetic patients without underlying coronary artery disease or hypertension is now recognized as a distinct clinical entity termed “diabetic cardiomyopathy” [23], which was first described by Rubler *et al.*, who reported data from four diabetic patients with heart failure without evidence of hypertension, coronary artery disease, valvular or congenital heart disease [24]. Increased left ventricle (LV) diastolic stiffness and relaxation disturbances are recognized as the earliest manifestation of diabetes-induced cardiac remodeling and have been noted in 27%–70%

of asymptomatic diabetic patients [25,26]. Of note, left ventricular hypertrophy, which is a relevant prognostic risk factor in heart disease, occurred more frequently in diabetic patients and is a major contributor for the increased ventricular stiffness and diastolic dysfunction [27]. LV systolic dysfunction supervenes only at later stages of DCM. A decreased LV systolic ejection fraction (LVEF) provides a good reflection of the severity of systolic dysfunction and heart failure. Though the pathogenesis and pathophysiology of DCM is multifactorial and poorly understood, current evidence suggests that diabetes affects cardiac remodeling through a variety of mechanisms (Figure 1), including over-activation of the renin-angiotensin system, insulin resistance, metabolic disturbances (hyperglycemia, hyperinsulinemia and hyperlipidemia), fibrosis and impairment of calcium homeostasis [28–30]. Given the common and increasing prevalence of diabetes in the general population, diabetic cardiomyopathy is a significant and growing public health concern.

Figure 1. The pathophysiology of diabetic cardiomyopathy. Diabetes-induced cardiac insulin resistance, glucose/lipid dysmetabolism and activation of the renin-angiotensin system promote the development and progression of diabetic cardiomyopathy (DCM). ER, endoplasmic reticulum; RAS, renin-angiotensin system.



Diabetic patients may take several years to develop overt DCM. In the early stage, a majority of the cases of DCM are subclinical, and patients may not have overt symptoms or signs of disease. Thus, the implementation of diagnostic strategies for DCM to identify the disease at its early stages would be important in the prevention and early treatment of DCM. Echocardiography and Doppler imaging are able to detect significant cardiac abnormalities before the onset of symptomatic HF. Diastolic dysfunction, characterized as HF with normal EF, is present in 75% of asymptomatic diabetic patients [31]. The mitral inflow patterns, early ventricular filling wave (E-wave) and the late ventricular filling wave (A-wave), the E/A ratio, the isovolumetric relaxation time (IVRT), cardiac stiffness and myocardial tissue velocities during the cardiac cycle can be assessed by echocardiography and tissue Doppler imaging [32,33]. With more sensitive techniques, like strain deformation imaging,

researchers observed that LV systolic function is impaired despite normal LVEF [34,35] and in 28% of patients with normal diastolic function, suggesting that systolic strain alteration may exist despite normal diastolic function and that diastolic dysfunction should not be considered the first marker of a preclinical form of DCM. Cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET) have recently emerged as a highly sensitive imaging tool for detecting myocardial metabolic changes, LV wall motion abnormalities, geometry and cardiac hypertrophy [36] and may serve as a new technique in the diagnosis of DCM at an early stage.

Treatment should begin as soon as the diagnosis of diastolic dysfunction is made, to prevent further development of heart failure. The management and treatment of DCM have focused on changes in lifestyle, improving glycemic control, treatment of dyslipidemia and management of the coexistent hypertension, coronary artery disease (CAD) and heart failure [37]. Regular physical exercise and limitation of fat and total energy intake remain the cornerstone of the management of overweight diabetic patients. Clinical studies have shown that lifestyle changes with diet and/or exercise interventions led to a significant decrease in the incidence of DCM among subjects with type 2 diabetes [38,39]. Hyperglycemia can directly impair biological processes important for the maintenance of normal cellular function and serve as the prime driver behind diabetic DCM. Improvement of glycemic control has been shown to be associated with better outcomes in diabetic microvascular complications in clinical trials [40,41]. However, many prospective randomized clinical trials, such as ACCORD (Action to Control Cardiovascular Risk in Diabetes) and ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), failed to conclusively demonstrate that aggressive glycemic control improves the cardiovascular prognosis of diabetic patients, especially those with advanced type 2 diabetes [41–43]. Different drug combinations, like metformin plus dipeptidyl peptidase-4 inhibitors/Glucagon-like peptide-1 mimetics, metformin plus pioglitazone, sulphonylurea or insulin, may be necessary for optimal glycemic control [37]. Treatment of dyslipidemia significantly reduces the incidence of major cardiovascular events, including DCM, in type 2 diabetic patients, and a reduction in low density lipoprotein cholesterol should be the primary goal for lipid modifying interventions [44,45]. Various vasoactive drugs, such as renin inhibitor, angiotensin convertase enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), beta adreno-receptor blockers and calcium channel blockers, have been used in the management of hypertension, CAD and HF and have been found to be beneficial for patients with DCM [46,47]. ACEIs and ARBs have demonstrated cardiovascular protection in diabetic patients [48,49]. Aliskiren is the first representative of a new class of orally active direct renin inhibitors and provides a more complete blockade of the renin-angiotensin system (RAS), effectively suppressing residual angiotensin II production and the counter-regulatory increase in plasma renin activity observed in patients receiving monotherapy with ACEIs or ARBs [50]. However, the combination therapy of aliskiren with ACEIs or ARBs in diabetic hypertensive patients with chronic kidney disease is controversial [51,52]. Currently, a combination therapy of aliskiren with ACEIs and ARBs is not recommended in patients with type 2 diabetes mellitus and renal impairment. Beta-blockers have been shown to prevent and even reverse cardiac remodeling, resulting in improved LV function and a reduction in mortality in diabetic and non-diabetic patients [53]. Beta-blockers should be given to all diabetic patients with any evidence of HF, unless specifically contraindicated. Calcium channel blockers are capable of reversing the intracellular calcium defects and preventing diabetes-induced myocardial changes and are safe and

effective as first-line or add-on therapies in diabetic hypertensive patients [54]. In addition to diabetic and heart failure therapies, other novel treatments are under investigation for DCM. Continued efforts to identify effective preventative strategies and treatments are essential.

3. Retinoic Acid and Retinoid Receptor Signaling

Retinoic acid (RA), the active metabolite of vitamin A (Figure 2A), is an important signaling molecule in embryonic development and in regulating cell survival, differentiation and death [55]. The precursors of RA have to be obtained from the diet, either as retinyl esters from animal sources or β -carotene from plants. In the circulation, retinol binds to the specific transport protein, retinol-binding protein 4 (RBP4), and forms a complex with transthyretin to prevent renal filtration and catabolism [56]. Retinol is taken up by target cells from the circulation through spontaneous diffusion across plasma membranes, fluxes that are dictated by its extracellular to intracellular concentration gradient [57], or through a cell surface receptor, STRA6 (stimulated by retinoic acid) [58]. Recent studies have shown that STRA6 mediated retinol uptake is only required in eye, and it is not critical for maintaining retinol availability in tissues that express it [59,60]. Intracellularly, retinol associates with cellular retinol-binding protein (CRBP) and is oxidized to retinaldehyde (rate-limiting) by two types of enzymes: alcohol dehydrogenase (ADH) of the medium-chain ADH family and short-chain dehydrogenase/reductase (SDR) [61,62]. Studies have demonstrated that the ADH enzymes are not essential for RA biosynthesis from a physiologically relevant supply of vitamin A during embryogenesis or adulthood and that SDR family members have been implicated in the regulation of RA homeostasis [63,64]. Retinaldehyde is further oxidized to all-*trans* retinoic acid (ATRA), irreversibly by retinaldehyde dehydrogenase (RALDH) [65]. After binding to cellular retinoic acid binding proteins (CRABP), ATRA is transported into the nucleus and binds to nuclear receptors to regulate gene transcription or delivered to cytochrome (CYP) enzymes for degradation [66,67]. Most of the biological effects of RA are mediated by retinoic acid receptors (RAR) and retinoid X receptors (RXR). Both have three subtypes, α , β and γ , and are members of the nuclear hormone receptor super-family. RAR and RXR modulate gene expression by acting as ligand-dependent transcription factors. RARs primarily bind to ATRA, and RXRs bind to a stereoisomer, 9-*cis*-RA. Upon ligand binding, receptors form dimers and bind to DNA motifs known as RA response elements (RAREs), located in the regulatory regions of target genes and which subsequently modulate the transcription of an array of target genes [68,69] RAR is activated only when heterodimerizing with RXRs. RXR modulates gene transcription by forming either homodimers or heterodimers with several other nuclear receptors, including RAR, the vitamin D receptor, peroxisome proliferator activated receptors (PPARs), farnesoid X receptors, the liver X receptor (LXR) and the thyroid hormone receptor. Therefore, RXR plays a key role in nuclear signaling pathways involving its dimeric partners. RAR and RXR have conserved structures with six regions (A–F) (Figure 2B). The N-terminal A/B region contains another transcription activation domain (AF-1) that functions autonomously and ligand independently. This domain contains many phosphorylation sites and is the target of multiple kinases. The central C region is the most conserved DNA-binding domain (DBD). The C-terminal contains a ligand-binding domain (LBD) and ligand-dependent transactivation domain (AF-2). In the absence of a ligand, RXR/RAR heterodimers are bound to DNA in a complex with corepressors (such as NCoR

(nuclear receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone) receptors) that actively repress transcription. Upon ligand binding, co-repressors are released, and co-activator complexes (including p160 family members, the CREB-binding protein and p300) are recruited to activate transcription. The transactivation of RAR and RXR is also regulated by phosphorylation. Signaling pathways initiated by Cdk7 and PKA are involved in the positive control of retinoid-regulated transcription [70,71]. PKC, Akt and JNK-induced phosphorylation leads to degradation and transrepression of RAR/RXR [72–74]. Several lines of evidence indicate that phosphorylation of RAR/RXR has a crucial role in the development of certain cancers [75,76]. The requirement for retinoic acid during embryogenesis (brain, heart, lung and limb formation) has been long appreciated [77], and deregulated retinoid signaling contributes to serious diseases, such as cancer and metabolic diseases [78–81]. Retinoids have been investigated extensively for their use in cancer prevention and treatment [82].

Figure 2. Retinoid metabolism and the structure of retinoid receptors. (A) Retinol binds to RBP4 (retinol binding protein 4) in plasma. RBP4 bonds to STRA6, resulting in the activation of the JAK2 signaling pathway. Retinol bound with cellular retinol-binding protein (CRBP) is converted to retinaldehyde by short-chain dehydrogenase/reductase (SDR); and then to all-*trans* retinoic acid (ATRA) by retinaldehyde dehydrogenase (RALDH); (B) Schematic representation of the functional domains and the major phosphorylation sites of RAR α (retinoic acid receptor α) and RXR α (retinoid X receptors α). The DNA-binding domain (DBD) and the ligand-binding domain (LBD) are schematically represented (not to scale). The functional AF-1 and AF-2 domains lie in the A/B and E regions, respectively. Phosphorylation sites are shown in a bold black line.






Figure 2. Cont.



4. Retinoic Acid Signaling Is Involved in the Development of Diabetes

To date, the impacts of vitamin A and retinoids on the energy metabolism of the liver, adipocytes, pancreatic β -cells and skeletal muscle in animals and humans have been demonstrated in basic and clinical investigations (Figure 3) [14,15,83–89]. There is increasing evidence that vitamin A metabolism is impaired, especially in poorly controlled DM [90,91]. Studies have shown a decreased plasma level of retinol in type 1 diabetic patients and in streptozotocin-induced diabetic animal models [92,93] and that dietary supplementation of vitamin A inhibits the development of type 1 diabetes [94]. Van Y. H. *et al.* reported that ATRA inhibits the development of type 1 diabetes by T regulatory-dependent suppression of interferon γ -producing T-cells [95], suggesting that the use of ATRA to induce immune tolerance may provide an effective method to inhibit type 1 DM. Although the plasma level of retinol is normal in type 2 DM, an increased serum level of RBP4 is observed. The increased serum RBP4 concentrations in type 2 diabetic patients may be associated with diabetes-related renal dysfunction, cardiovascular disease and imbalances in lipid metabolism [83,96,97]. Lowering the RBP4 level by ATRA or a synthetic retinoid, fenretinide, leads to improved insulin action and glucose tolerance in insulin-resistant obese mice [91,92,98–100]. Recent studies have shown that holo-RBP/STRA6 is involved in the regulation of activation of the JAK2/STAT5 cascade and insulin resistance, by inducing the suppressor of cytokine signaling 3 (SOCS3) and PPAR γ expression [59,101]. RBP4-mediated inhibition of insulin signaling is also regulated by promoting the expression of proinflammatory cytokines through a toll-like receptor 4- and c-Jun N-terminal kinase (JNK)-dependent and retinol-independent mechanism [10]. Activation of RAR/RXR-mediated signaling also has anti-diabetic effects in type 2 DM. In 1997, Mukherjee R. *et al.* first reported that a synthetic activator of RXR functions as an insulin sensitizer, markedly decreasing serum glucose and insulin levels in mouse models of type 2 diabetes and obesity [102]. Treatment of diabetic (db/db) mice with LG268 (selective RXR ligand) significantly increased insulin-stimulated glucose transport in skeletal muscle, via increasing insulin-stimulated insulin receptor substrate 1 (IRS1) tyrosine phosphorylation and AKT phosphorylation [103]. Our group also reported that ATRA, Am580 (RAR α selective ligand) and LGD1069 (RXR ligand) lowered the blood glucose level and improved insulin resistance in a Zucker diabetic fatty (ZDF) rat type 2 diabetic model [6,7].

Figure 3. Retinoid-mediated signaling in the regulation of glucose/lipid metabolism. The schematic diagram represents the involvement of retinoid signaling components in the regulation of glucose/lipid metabolism in the development of obesity and diabetes. RBP4, retinol binding protein 4; SDR, short-chain dehydrogenase/reductase; RALDH, retinaldehyde dehydrogenase; HFD, high fat diet; RALDH^{-/-}, RALDH knockout mice.



Obesity has historically been shown to be a risk factor for type 2 diabetes. During the past 50 years, both clinical and animal studies have suggested the involvement of retinoids and RAR/RXR signaling in the regulation of lipid metabolism and obesity. Supplementation of obese rats with high levels of dietary vitamin A reduced body weight gain and visceral adiposity and improved insulin sensitivity, by decreasing soleus muscle PTP1B (protein tyrosine phosphatase 1B) levels and increasing insulin receptor phosphorylation [104]. Retinoic acid treatment also resulted in weight loss, decreased adiposity and increased insulin sensitivity, through promoting lipid oxidation capacity in skeletal muscle and liver in several lean and/or obese mouse models [89,105,106]. Similarly, a diet deficient in vitamin A led to an increase in body weight and adiposity in mice [107,108]. Studies have shown that ATRA represses obesity and insulin resistance in a type 2 diabetic animal model, through activation of proliferation-activated receptor δ (PPAR δ) [13]. ATRA-induced body fat loss correlates with the activation of brown adipose tissue, reduced adipogenic/lipogenic capabilities, increased capabilities for oxidative metabolism in white adipose tissue depots and increased lipid oxidation capacity in skeletal muscle and adipocytes [106,109]. Retinoic acid synthesizing enzymes (RALDH) are also involved in the regulation of lipid metabolism and high fat diet-induced insulin resistance [110]. The polymorphism in the promoter of the *CRABP2* gene is associated with increased plasma low-density lipoprotein cholesterol (LDL-C) concentrations in familial hypercholesterolemia patients [111]. These studies indicate that altered expression/activation of RA signaling closely correlates with the development of DM and insulin resistance.

5. Retinoid Receptor-Mediated Signaling and Diabetic Cardiomyopathy

5.1. Retinoid Receptor-Mediated Signaling in Cardiac Remodeling

Cardiac remodeling has a major role in the progression to HF, which is associated with alterations in the ventricular structure and function, resulting from myocardial injury, pressure or volume overload. At the cellular level, cardiac remodeling is characterized by cardiomyocyte hypertrophy, fibroblast hyperplasia accompanied by an increase in collagen deposition within the interstitial matrix (fibrosis) and cell death. It is well known that RA signaling is required for cardiac development [112–115]. Changes in RA homeostasis (lacking or excess of RA) result in severe malformations during cardiogenesis, suggesting that a precise tissue concentration of RA is indispensable for the proper induction of signaling pathways important for normal myocardial cell growth and differentiation in early embryonic stages. RA signaling has been implicated in the regulation of cell differentiation, proliferation and apoptosis [116,117], and a substantial body of knowledge has accumulated on its role in the regulation of cardiomyocyte growth, apoptosis and cellular function in response to various pathophysiological stimuli. Using an *in vitro* cultured cardiomyocyte model, we and others have demonstrated that RA suppresses myocardial cell growth in response to hypertrophic stimuli, including cyclic stretch, angiotensin II (Ang II), endothelin-1 and phenylephrine [118–121]. Ang II-induced cardiac fibroblast growth and collagen secretion are also inhibited by RA [122]. Chronic RA treatment attenuated tobacco smoke exposure-induced cardiac hypertrophy and LV dysfunction in rats [123] and prevented medial thickening of intramyocardial and intrarenal arteries and ventricular fibrosis during the development of hypertension in SHR (Spontaneously Hypertensive) rats [124]. In a rat model of myocardial infarction, coronary occlusion-induced LV morphological (hypertrophy) and functional changes were improved by RA treatment [125]. Using a chronic rat pressure-overload model, our group demonstrated that RA inhibits cardiomyocyte apoptosis and fibrosis and improves both systolic and diastolic heart function, through the inhibition of the oxidative stress-induced activation of MAP kinase pathways and the expression of renin-angiotensin system (RAS) components [126]. These studies suggest that activation of the RAR/RXR signaling pathway has an important role in preventing the transition from compensatory hypertrophy to heart failure.

Diabetic cardiomyopathy represents a distinct structural and functional disorder of the myocardium characterized by cardiac hypertrophy and diastolic heart failure at the early stage, progressing to overt systolic heart failure at the later stage. Using *in vitro* primary cultured cardiomyocytes, we have demonstrated that high glucose-induced apoptosis and reactive oxygen species (ROS) generation was prevented by both RAR and RXR agonists. Silencing the expression of RAR α and RXR α , by small interference RNA, promoted apoptosis under normal conditions and significantly enhanced high glucose-induced apoptosis [8]. Using an *in vivo* type 2 diabetic animal model, we provided additional evidence supporting a role of RAR α and RXR α in the diabetes-induced development of cardiac remodeling. We have shown that chronic treatment with the RAR α selective ligand, Am580, and the RXR selective ligand, LGD1069, significantly improved diastolic dysfunction and attenuated LV hypertrophy, fibrosis, apoptosis and inflammatory responses in ZDF rats [7]. Our data indicate that

RA/RAR/RXR-mediated signaling may serve as an alternative therapeutic target in the prevention and treatment of diabetic cardiomyopathy.

5.2. Mechanisms Involved in Retinoid Receptor Signaling Regulated Diabetic Cardiomyopathy

5.2.1. Activation of RAR/RXR Signaling Improves Cardiac Insulin Signaling and Glucose/Lipid Metabolism

In type 1 and type 2 DM, glucose uptake, glycolysis and pyruvate oxidation are impaired. Additionally, a lack of insulin function augments lipolysis and the release of fatty acids (FA) from adipose tissue. Derangements in cardiac lipid and glucose metabolism are becoming recognized as an early event in the deterioration of heart function in diabetes. Hyperglycemia is the main driving force at all stages of diabetic cardiomyopathy. It triggers various adaptive and maladaptive responses, which lead synergistically to the development of heart failure [29,127]. Under normal physiological conditions, glucose is one of the major carbohydrates utilized by the heart. In type 1 diabetic animals, reduced *GLUT* gene and protein expression compromises cardiac glucose uptake and oxidation [128]. In obese or type 2 diabetic animals, cardiac glucose uptake is reduced as a consequence of reduced GLUT4 protein and impaired insulin signaling [129,130]. The impaired glucose uptake forces cardiomyocytes to rely less on glucose metabolism and more on β -oxidation of free fatty acids (FA) for energy production. This dramatic shift results in the loss of metabolic flexibility and decreased cardiac efficiency in diabetic heart. Moreover, augmented FA oxidation increases lipid deposition and promotes insulin resistance. Lipid accumulation within cardiomyocytes is associated with impaired contractile function [131]. FA metabolism also generates a number of toxic intermediates that accumulate in myocardial cells, resulting in lipotoxicity, and contributes to the initiation and development of diabetic cardiomyopathy [132–136]. Oxidative stress, the imbalance between reactive oxygen species production and the breakdown by endogenous antioxidants, has been implicated in the onset and progression of cardiovascular diseases, such as congestive heart failure and diabetic cardiomyopathy [137,138]. Studies have shown that hyperglycemia significantly enhances free radical formation and mitochondrial generation of superoxide, which increases oxidative stress and activates cellular signal transduction and cardiac cell death, leading to diabetic cardiomyopathy [8,22,139,140]. Increased lipid accumulation and FA β -oxidation in diabetic myocardium also leads to overwhelming generation of ROS, which is associated with impaired insulin signaling and the development of heart dysfunction [141,142]. As such, insulin resistance, increased FA and hyperglycemia can be considered triggers for the cardiac phenotype in diabetes. An understanding of the cellular effects and mechanisms of these metabolic disturbances on cardiomyocytes will be important in predicting the structural and functional cardiac consequences and in developing therapeutic approaches for the treatment of DM-induced cardiac remodeling.

A number of studies have shown that RA lowers plasma glucose levels and improves insulin resistance in adipocytes, skeletal muscle and liver tissues [14,15,83–89]. Our group further provided evidence that the activation of RAR/RXR signaling improves cardiac glucose metabolism in ZDF rats [7]. We demonstrated that activation of RAR α and RXR by Am580 and LGD1069 not only improved systemic glucose homeostasis, but also had a significant effect on cardiac glucose metabolism. Impaired Akt/GSK3 β insulin signaling and decreased gene expression of GLUT1,

GLUT4, aldolase A and hexokinase 2, in ZDF rat hearts, was improved by Am580 or LGD1069 treatment, indicating that the activation of RAR and RXR signaling rescued the impaired cardiac insulin signaling and promoted glucose transportation and utilization. Diabetes-induced cardiac oxidative stress, apoptosis and activation of MAP kinases and NF- κ B pathways were inhibited by Am580 and LGD1069. Thus, it is likely that the beneficial effect of Am580 or LGD1069 on diabetic cardiomyopathy is mediated at least partially by reducing glucotoxicity-induced cardiac oxidative stress and activation of apoptotic signaling. RAR and RXR-mediated signaling has an important role in the regulation of lipid metabolism and the development of obesity. However, the functional role of RAR and RXR in the regulation of cardiac lipid metabolism remains unclear. Previous studies have shown that ATRA suppresses hyperlipidemia and obesity and blocks adipogenesis, by enhancing FA oxidation and energy dissipation, through ATRA-induced activation of PPAR β/δ and RAR in adipocytes and liver [13,106]. We observed that ATRA suppressed body weight gain and increased cardiac FA β -oxidation in ZDF rats, following two weeks of treatment. Am580 had a similar effect on inhibiting body weight gain, cardiac FA uptake, β -oxidation and intracardiac lipid accumulation in ZDF rats, following 16 weeks of treatment [7]. These data suggest that ATRA and Am580 may alter substrate metabolism in diabetic heart, through rebalancing the utilization between glucose and FA, which further leads to improvement in cardiac efficiency and function. Though Am580 had a favorable effect on cardiac lipid metabolism, it had no effect on the increased plasma cholesterol and triglyceride levels. Am580, a selective agonist of RAR α , is not an activator of PPAR β/δ , and thus, the mechanisms whereby Am580 regulates cardiac lipid metabolism and suppresses obesity may be different than those of ATRA. Compared to ATRA and Am580, LGD1069 further promoted body weight gain and hyperlipidemia following 16 weeks of treatment and significantly increased intracardiac lipid deposition in ZDF rat hearts. This is not consistent with previous studies, which have shown that RXR ligands, including LGD1069, decrease triglycerides and increase HDL levels in db/db or ob/ob mice [102,143]. It has been described that RXR can form permissive heterodimers with PPARs, the farnesoid-X-receptor and liver-X-receptors (LXR) and that these can be activated by both RXR-specific and partner-specific ligands [144]. We have observed that PPAR α and LXR are activated by LGD1069 and that these receptors are also involved in the regulation of lipid metabolism [145,146]. The effect of LG1069 on cardiac lipid homeostasis we observed may be regulated not only through activation of RXR, but also PPAR and LXR. Therefore, studies with a receptor-subtype-specific ligand and receptor knockout models are critical to understand the downstream mechanisms involved in RAR/RXR-mediated metabolic signaling pathways.

5.2.2. RAR/RXR Signaling in the Regulation of Cardiac NF- κ B-Mediated Inflammatory Responses

Cardiac inflammation is one of the diverse mechanisms that are involved in the progression of diabetic cardiomyopathy [147–149]. Sustained increases in the levels of pro-inflammatory cytokines and chemokines, such as tumor necrosis factor- α (TNF- α), monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6), could directly and indirectly cause cardiac tissue injury, such as myocardial fibrosis, necrosis and apoptosis, which inevitably leads to cardiac diastolic and subsequent systolic dysfunction [150,151]. Pro-inflammatory cytokine expression is under the control of the ubiquitous and inducible transcription factor, NF- κ B (nuclear factor-kappa B), which is activated by a variety of

pathological stimuli, such as inflammatory cytokines, hyperglycemia, elevated free fatty acid levels in plasma, oxidative stress, angiotensin II, lipoproteins and anoxia [152,153]. Inactive NF- κ B is primarily located in the cytoplasm in association with the inhibitor of κ B (I κ B). Following exposure to various stimuli, I κ B is phosphorylated by I κ B kinases (IKKs) and degraded by the ubiquitin proteasome pathway. A large body of evidence suggests that NF- κ B activation occurs in a sustained manner in diabetes, in association with elevated blood glucose levels and inflammation [154–157]. The involvement of NF- κ B in diabetic cardiomyopathy has been demonstrated in several studies on diabetic rat hearts [6,7,158,159]. Retinoids act as potent anti-inflammation agents that exert beneficial responses in the cardiovascular system [160,161]. Vitamin A and its metabolites inhibit several types of inflammatory reactions [162,163], and activated NF- κ B signaling is associated with an increased inflammatory response in vitamin A deficiency [164–166]. The activation of RXR inhibits high glucose-induced upregulation of inflammation, by suppressing the activation of the NADPH oxidase-NF- κ B pathway in human endothelial cells [167]. These data suggest that there is an interaction between RAR/RXR signaling and the NF- κ B-mediated inflammatory pathway. We have demonstrated that the activation of RAR and RXR inhibits the activation of NF- κ B and NF- κ B-mediated gene expression of IL-6, TNF- α and MCP-1, *in vitro* and *in vivo* [6,7], indicating that the protective effects of RAR and RXR ligands on cardiomyocytes are mediated (at least in part) through the regulation of NF- κ B signaling. The molecular mechanisms by which RA inhibits the activation of NF- κ B appears to involve the inhibition of phosphorylation of IKK/I κ B α and degradation of I κ B α , through activation of PP2A (protein phosphatase 2A). The interactions between RAR/RXR and NF- κ B signaling may have important implications in understanding the mechanisms involved in the development of diabetic cardiomyopathy.

5.2.3. RAR/RXR Signaling in the Regulation of the Renin-Angiotensin System

The renin-angiotensin system (RAS) and its primary effector peptide, angiotensin II (Ang II), is a key regulatory system in blood pressure and volume homeostasis and has an essential role in the pathophysiology of heart failure. The RAS has been an important drug target for therapeutic intervention: Ang II receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEi) and renin inhibitors reduce heart failure-related morbidity and mortality [168,169]. Accumulating evidence suggests that RAS blockade also has favorable effects on the parameters of glucose metabolism and the incidence of diabetes [170]. Expression/activation of the RAS has been implicated in the development of diabetic cardiomyopathy. Abnormal production of Ang II is associated with a high index of cardiomyocyte apoptosis in human and animal models of diabetes [171,172]. Hyperglycemia stimulates cardiomyocyte production of Ang II via an upregulation of most of the cellular components of the RAS [172–176]. The interaction between RA signaling and the RAS has previously been reported [126,177–179]. RA negatively regulates renal RAS components in rats with experimental nephritis [177]. Downregulation of AT₁R mRNA and the repressed Ang II-stimulated AT₁R promoter activity are observed in RA-treated vascular smooth muscle cells [178,180]. It has been shown that RA downregulates the expression of AT₁R and upregulates ACE2 in SHR hearts, which is accompanied by a decrease in blood pressure [179,181]. Our group also demonstrated that the increased plasma level of Ang II, upregulated gene expression of cardiac and renal renin, angiotensinogen (AGT), ACE and AT₁R

are inhibited by ATRA in pressure overloaded rats and mechanically stretched cardiomyocytes [126], indicating that RA signaling is involved in regulating RAS components during the development of cardiac remodeling. We have reported recently that hyperglycemia-induced apoptosis and ROS production are inhibited by the AT₁R blocker, indicating that Ang II-activated AT₁R signaling contributes to hyperglycemia-induced cellular injury [8]. ATRA inhibited high glucose- and Ang II-induced cell apoptosis and ROS production. High glucose-induced gene expression of AGT, renin, AT₁R and intracardiac Ang II production were significantly inhibited by ATRA. On the other hand, silencing the expression of RAR α or RXR α increased the basal level of the gene expression of AGT and dramatically increased AGT expression in combination with high glucose stimulation. Our results suggest that a certain level of expression of RAR α and RXR α is required in the regulation of the expression of AGT, under normal and hyperglycemic conditions, and that RAR α /RXR α heterodimer-mediated signaling negatively regulates RAS components and AT₁R-mediated signaling events. By inhibiting the rate-limiting step in the renin-angiotensin cascade, RA signaling might have some advantages over the RAS inhibitors widely used in the clinic.

5.2.4. Does Impaired RAR/RXR Signaling Contribute to the Development of DCM?


The high degree of conservation of RAR and RXR across vertebrates and specific patterns of expression during embryogenesis and in adult tissues suggests that each receptor performs a specific function [182]. Targeted disruption of RAR and RXR, mainly RAR α and RXR α in the embryonic stage, resulted in early postnatal or embryonic lethality and heart failure [183,184], suggesting that RAR α and RXR α are the two main receptor subtypes that are involved in the regulation of cardiomyocyte differentiation and function. It has been reported that decreased cardiac expression of RXR α is involved in the altered myocardial metabolic phenotype in severe heart failure and that downregulation of RXR α may be responsible for impairment in free fatty acid oxidative pathways in the failing heart [185,186]. We have recently demonstrated that nuclear expression of RAR α and RXR α was significantly downregulated in high glucose-stimulated cardiomyocytes and in diabetic rat myocardium [7,8,187]. High glucose stimulation also repressed physiological doses of RA-induced transcriptional activity of RAR and RXR, suggesting that a relative “RA-resistance” developed in response to hyperglycemia. Whether the alteration of RAR/RXR signaling is directly associated with the development of diabetes-induced cardiac remodeling remains unknown. We have observed that silencing the expression of RAR α and RXR α in cardiomyocytes promotes high glucose-induced expression/activation of cardiac RAS components and apoptosis *in vitro* [8]. To further understand the role of RAR α and RXR α in the regulation of cellular function in adult cardiomyocytes, in response to pathological stimuli, we generated tamoxifen-inducible RAR α and RXR α cardiac-specific knockout mice (RAR α KO and RXR α KO). Cardiac-specific gene deletion of RAR α and RXR α results in diastolic dysfunction, which is associated with increased oxidative stress and apoptosis [188]. These results suggest that RAR α and RXR α -mediated signaling is required to preserve normal cardiomyocyte function and that impairment of RAR/RXR signaling may accelerate the development of heart failure in response to pathological stimuli. Understanding the mechanisms underlying the impaired cardiac expression/activation of RAR α and RXR α will be important in determining the novel mechanisms leading to heart failure.

Retinoid receptor transcriptional activity is regulated by factors both intrinsic and extrinsic to the receptor complex. Although ligand binding is thought to be the primary means of activation of RAR and RXR, the transcriptional activity of RAR and RXR is also modulated by protein kinase-mediated phosphorylation and degradation [189]. RAR α and RXR α contain multiple phosphorylation sites (Figure 2) and are substrates for a variety of serine/threonine kinases, including PKA, PKC, Cdk7 and MAP kinases [70,72,190–192]. Phosphorylation of RXR α at serine 260, a consensus MAP kinase site, results in the attenuation of ligand-dependent transactivation by the vitamin D₃ receptor/RXR α complex [193]. Stress-induced phosphorylation of RXR α , through MAPK kinase 4 (MKK4) and JNK, results in the suppression of retinoid signaling in COS-7 cells (derived from CV-1 simian cells transformed by an origin-defective mutant of SV40) [74,194]. JNK activation by oxidative stress suppresses retinoid signaling through proteasomal degradation of RAR α in hepatic cells [195]. These data suggest that oxidative stress/MAP kinases-regulated phosphorylation/degradation of RAR and RXR may have an important role in pathological stimuli-induced impairment of RAR/RXR signaling. We have recently reported that high glucose induces serine phosphorylation of RAR α and RXR α in cardiomyocytes and that inhibition of intracellular ROS generation and activation of the JNK pathway prevents the downregulated expression and transcriptional repression of RAR α and RXR α in cardiomyocytes. On the other hand, H₂O₂ stimulation or activation of JNK suppressed the expression and ligand-induced promoter activity of RAR α and RXR α [187]. Based on these data, it is likely that diabetes-induced oxidative stress and activation of JNK promotes degradation and transcriptional inhibition of RAR α and RXR α , through phosphorylation of RAR α and RXR α at specific phosphorylation sites. Interestingly, silencing the expression of RAR α and RXR α in cardiomyocytes promoted the activation of the JNK pathway *in vitro* [187] and *in vivo* (in the hearts of RAR α KO and RXR α KO mice) [188], suggesting that impaired RAR/RXR signaling and oxidative stress/the JNK pathway form a vicious circle, which may significantly contribute to diabetes-induced cardiac remodeling (Figure 4). Identifying the phosphorylation site that is specifically linked to JNK-mediated degradation and transcriptional inhibition of RAR α and RXR α will have functional significance in understanding the mechanism of DCM and in developing a therapeutic strategy for management.

6. Conclusions

Retinoic acid and RAR/RXR-mediated signaling are increasingly recognized as mediators of diabetes and obesity. Impaired RAR/RXR signaling may contribute to the development of diabetic cardiomyopathy and diastolic heart failure. Experimental data have provided strong evidence that RAR and RXR function as important transcriptional regulators in the development of diabetes-induced cardiac remodeling and heart failure, through the regulation of the cardiac renin-angiotensin system, glucose/lipid metabolism and oxidative stress associated signaling pathways. Therefore, retinoic acid and RAR/RXR-mediated signaling may represent a novel target for developing therapeutic approaches for the treatment and prevention of diastolic heart failure and DCM.

Figure 4. Schematic of the interaction between diabetes mellitus (DM), JNK and impaired RAR/RXR signaling in DCM. Mechanisms of DM-induced oxidative stress and JNK activation in the regulation of phosphorylation/transcriptional inhibition of RAR α and RXR α and the development of DCM are proposed.



Acknowledgments

This work was supported by a grant from the National Institutes of Health (1R01 HL091902). The material is the result of work supported with resources and the use of facilities at the Central Texas Veterans Health Care System, Temple, Texas, USA.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Battiprolu, P.K.; Gillette, T.G.; Wang, Z.V.; Lavandero, S.; Hill, J.A. Diabetic Cardiomyopathy: Mechanisms, Therapeutic Targets. *Drug Discov. Today Dis. Mech.* **2010**, *7*, e135–e143.
2. Murarka, S.; Movahed, M.R. Diabetic cardiomyopathy. *J. Card. Fail.* **2010**, *16*, 971–979.
3. Mariappan, N.; Elks, C.M.; Sriramula, S.; Guggilam, A.; Liu, Z.; Borkhsenius, O.; Francis, J. NF- κ B-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. *Cardiovasc. Res.* **2010**, *85*, 473–483.
4. Westermann, D.; Rutschow, S.; van Linthout, S.; Linderer, A.; Bucker-Gartner, C.; Sobirey, M.; Riad, A.; Pauschinger, M.; Schultheiss, H.P.; Tschope, C. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. *Diabetologia* **2006**, *49*, 2507–2513.
5. Li, C.J.; Lv, L.; Li, H.; Yu, D.M. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by α -lipoic acid. *Cardiovasc. Diabetol.* **2012**, *11*, doi:10.1186/1475-2840-11-73.

6. Nizamutdinova, I.T.; Guleria, R.S.; Singh, A.B.; Kendall, J.A., Jr.; Baker, K.M.; Pan, J. Retinoic acid protects cardiomyocytes from high glucose-induced apoptosis via inhibition of sustained activation of NF- κ B signaling. *J. Cell. Physiol.* **2013**, *228*, 380–392.
7. Guleria, R.S.; Singh, A.B.; Nizamutdinova, I.T.; Souslova, T.; Mohammad, A.A.; Kendall, J.A., Jr.; Baker, K.M.; Pan, J. Activation of retinoid receptor-mediated signaling ameliorates diabetes-induced cardiac dysfunction in Zucker diabetic rats. *J. Mol. Cell. Cardiol.* **2013**, *57*, 106–118.
8. Guleria, R.S.; Choudhary, R.; Tanaka, T.; Baker, K.M.; Pan, J. Retinoic acid receptor-mediated signaling protects cardiomyocytes from hyperglycemia induced apoptosis: Role of the renin-angiotensin system. *J. Cell. Physiol.* **2011**, *226*, 1292–1307.
9. Frey, S.K.; Vogel, S. Vitamin A metabolism and adipose tissue biology. *Nutrients* **2011**, *3*, 27–39.
10. Norseen, J.; Hosooka, T.; Hammarstedt, A.; Yore, M.M.; Kant, S.; Aryal, P.; Kiernan, U.A.; Phillips, D.A.; Maruyama, H.; Kraus, B.J.; *et al.* Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. *Mol. Cell. Biol.* **2012**, *32*, 2010–2019.
11. Raghov, R. Metabolic balancing acts of vitamin A in type-2 diabetes and obesity. *World J. Diabetes* **2012**, *3*, 174–177.
12. Kiefer, F.W.; Vernochet, C.; O'Brien, P.; Spoerl, S.; Brown, J.D.; Nallamshetty, S.; Zeyda, M.; Stulnig, T.M.; Cohen, D.E.; Kahn, C.R.; *et al.* Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. *Nat. Med.* **2012**, *18*, 918–925.
13. Berry, D.C.; Noy, N. All-*trans*-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor β/δ and retinoic acid receptor. *Mol. Cell. Biol.* **2009**, *29*, 3286–3296.
14. Ziouzenkova, O.; Orasanu, G.; Sharlach, M.; Akiyama, T.E.; Berger, J.P.; Viereck, J.; Hamilton, J.A.; Tang, G.; Dolnikowski, G.G.; Vogel, S.; *et al.* Retinaldehyde represses adipogenesis and diet-induced obesity. *Nat. Med.* **2007**, *13*, 695–702.
15. Berry, D.C.; DeSantis, D.; Soltanian, H.; Croniger, C.M.; Noy, N. Retinoic acid upregulates preadipocyte genes to block adipogenesis and suppress diet-induced obesity. *Diabetes* **2012**, *61*, 1112–1121.
16. Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res. Clin. Pract.* **2010**, *87*, 4–14.
17. Grundy, S.M.; Benjamin, I.J.; Burke, G.L.; Chait, A.; Eckel, R.H.; Howard, B.V.; Mitch, W.; Smith, S.C., Jr.; Sowers, J.R. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. *Circulation* **1999**, *100*, 1134–1146.
18. Kannel, W.B. Incidence and epidemiology of heart failure. *Heart Fail. Rev.* **2000**, *5*, 167–173.
19. Liu, L.; Eisen, H.J. Epidemiology of heart failure and scope of the problem. *Cardiol. Clin.* **2014**, *32*, 1–8.

20. Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; *et al.* Executive summary: Heart disease and stroke statistics—2013 update: A report from the American Heart Association. *Circulation* **2013**, *127*, 143–152.
21. Galderisi, M.; Anderson, K.M.; Wilson, P.W.; Levy, D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). *Am. J. Cardiol.* **1991**, *68*, 85–89.
22. Rutter, M.K.; Parise, H.; Benjamin, E.J.; Levy, D.; Larson, M.G.; Meigs, J.B.; Nesto, R.W.; Wilson, P.W.; Vasan, R.S. Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the Framingham Heart Study. *Circulation* **2003**, *107*, 448–454.
23. Battiprolu, P.K.; Lopez-Crisosto, C.; Wang, Z.V.; Nemchenko, A.; Lavandero, S.; Hill, J.A. Diabetic cardiomyopathy and metabolic remodeling of the heart. *Life Sci.* **2013**, *92*, 609–615.
24. Rubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W.; Grishman, A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. *Am. J. Cardiol.* **1972**, *30*, 595–602.
25. Patil, M.B.; Burji, N.P. Echocardiographic evaluation of diastolic dysfunction in asymptomatic type 2 diabetes mellitus. *J. Assoc. Physicians India* **2012**, *60*, 23–26.
26. Paillolle, C.; Dahan, M.; Paycha, F.; Solal, A.C.; Passa, P.; Gourgon, R. Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic patients. *Am. J. Cardiol.* **1989**, *64*, 1010–1016.
27. Van Heerebeek, L.; Somsen, A.; Paulus, W.J. The failing diabetic heart: Focus on diastolic left ventricular dysfunction. *Curr. Diab. Rep.* **2009**, *9*, 79–86.
28. Mandavia, C.H.; Aroor, A.R.; Demarco, V.G.; Sowers, J.R. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. *Life Sci.* **2013**, *92*, 601–608.
29. Tillquist, M.N.; Maddox, T.M. Update on diabetic cardiomyopathy: Inches forward, miles to go. *Curr. Diab. Rep.* **2012**, *12*, 305–313.
30. Bugger, H.; Abel, E.D. Molecular mechanisms of diabetic cardiomyopathy. *Diabetologia* **2014**, *57*, 660–671.
31. Boyer, J.K.; Thanigaraj, S.; Schechtman, K.B.; Perez, J.E. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. *Am. J. Cardiol.* **2004**, *93*, 870–875.
32. Galderisi, M. Diastolic dysfunction and diabetic cardiomyopathy: Evaluation by Doppler echocardiography. *J. Am. Coll. Cardiol.* **2006**, *48*, 1548–1551.
33. Khouri, S.J.; Maly, G.T.; Suh, D.D.; Walsh, T.E. A practical approach to the echocardiographic evaluation of diastolic function. *J. Am. Soc. Echocardiogr.* **2004**, *17*, 290–297.
34. Ng, A.C.; Delgado, V.; Bertini, M.; van der Meer, R.W.; Rijzewijk, L.J.; Shanks, M.; Nucifora, G.; Smit, J.W.; Diamant, M.; Romijn, J.A.; *et al.* Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. *Am. J. Cardiol.* **2009**, *104*, 1398–1401.

35. Ernande, L.; Bergerot, C.; Rietzschel, E.R.; de Buyzere, M.L.; Thibault, H.; Pignonblanc, P.G.; Croisille, P.; Ovize, M.; Groisne, L.; Moulin, P.; *et al.* Diastolic dysfunction in patients with type 2 diabetes mellitus: Is it really the first marker of diabetic cardiomyopathy? *J. Am. Soc. Echocardiogr.* **2011**, *24*, 1268–1275.
36. Jeudy, J.; White, C.S. Cardiac magnetic resonance imaging: Techniques and principles. *Semin. Roentgenol.* **2008**, *43*, 173–182.
37. Pappachan, J.M.; Varughese, G.I.; Sriraman, R.; Arunagirinathan, G. Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. *World J. Diabetes* **2013**, *4*, 177–189.
38. Li, G.; Hu, Y.; Yang, W.; Jiang, Y.; Wang, J.; Xiao, J.; Hu, Z.; Pan, X.; Howard, B.V.; Bennett, P.H. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: The DA Qing IGT.; Diabetes Study. *Diabetes Res. Clin. Pract.* **2002**, *58*, 193–200.
39. Aguiar, E.J.; Morgan, P.J.; Collins, C.E.; Plotnikoff, R.C.; Callister, R. Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: A systematic review with meta-analysis. *Int. J. Behav. Nutr. Phys. Act.* **2014**, *11*, doi:10.1186/1479-5868-11-2.
40. Ismail-Beigi, F.; Craven, T.; Banerji, M.A.; Basile, J.; Calles, J.; Cohen, R.M.; Cuddihy, R.; Cushman, W.C.; Genuth, S.; Grimm, R.H., Jr.; *et al.* Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. *Lancet* **2010**, *376*, 419–430.
41. Hemmingsen, B.; Lund, S.S.; Gluud, C.; Vaag, A.; Almdal, T.P.; Hemmingsen, C.; Wetterslev, J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. *Cochrane Database Syst. Rev.* **2013**, *11*, doi:10.1002/14651858.CD008143.pub2.
42. Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; Grimm, R.H., Jr.; *et al.* Effects of intensive glucose lowering in type 2 diabetes. *N. Engl. J. Med.* **2008**, *358*, 2545–2559.
43. Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; *et al.* Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N. Engl. J. Med.* **2008**, *358*, 2560–2572.
44. Briel, M.; Ferreira-Gonzalez, I.; You, J.J.; Karanicolas, P.J.; Akl, E.A.; Wu, P.; Blechacz, B.; Bassler, D.; Wei, X.; Sharman, A.; *et al.* Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. *BMJ* **2009**, *338*, doi:10.1136/bmj.b92.
45. Robinson, J.G.; Wang, S.; Jacobson, T.A. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B *versus* low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. *Am. J. Cardiol.* **2012**, *110*, 1468–1476.
46. Huynh, K.; Bernardo, B.C.; McMullen, J.R.; Ritchie, R.H. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. *Pharmacol. Ther.* **2014**, *142*, 375–415.

47. Voulgari, C.; Papadogiannis, D.; Tentolouris, N. Diabetic cardiomyopathy: From the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. *Vasc. Health Risk Manag.* **2010**, *6*, 883–903.
48. Shekelle, P.G.; Rich, M.W.; Morton, S.C.; Atkinson, C.S.; Tu, W.; Maglione, M.; Rhodes, S.; Barrett, M.; Fonarow, G.C.; Greenberg, B.; *et al.* Efficacy of angiotensin-converting enzyme inhibitors and β -blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. *J. Am. Coll. Cardiol.* **2003**, *41*, 1529–1538.
49. Kawasaki, D.; Kosugi, K.; Waki, H.; Yamamoto, K.; Tsujino, T.; Masuyama, T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients—Reversal by chronic angiotensin II type 1A receptor blockade. *Circ. J.* **2007**, *71*, 524–529.
50. Riccioni, G. The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient. *Ther. Adv. Endocrinol. Metab.* **2013**, *4*, 139–145.
51. Parving, H.H.; Brenner, B.M.; McMurray, J.J.; de Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaidis, M.; *et al.* Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N. Engl. J. Med.* **2012**, *367*, 2204–2213.
52. Wu, M.T.; Tung, S.C.; Hsu, K.T.; Lee, C.T. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial. *J. Renin-Angiotensin-Aldosterone Syst.* **2012**, doi:10.1177/1470320312467560.
53. Fonarow, G.C. A review of evidence-based β -blockers in special populations with heart failure. *Rev. Cardiovasc. Med.* **2008**, *9*, 84–95.
54. Grossman, E.; Messerli, F.H. Calcium antagonists. *Prog. Cardiovasc. Dis.* **2004**, *47*, 34–57.
55. Rhinn, M.; Dolle, P. Retinoic acid signalling during development. *Development* **2012**, *139*, 843–858.
56. Naylor, H.M.; Newcomer, M.E. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. *Biochemistry* **1999**, *38*, 2647–2653.
57. Noy, N.; Xu, Z.J. Interactions of retinol with binding proteins: Implications for the mechanism of uptake by cells. *Biochemistry* **1990**, *29*, 3878–3883.
58. Kawaguchi, R.; Yu, J.; Honda, J.; Hu, J.; Whitelegge, J.; Ping, P.; Wiita, P.; Bok, D.; Sun, H. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. *Science* **2007**, *315*, 820–825.
59. Berry, D.C.; Jacobs, H.; Marwarha, G.; Gely-Pernot, A.; O’Byrne, S.M.; DeSantis, D.; Klopfenstein, M.; Feret, B.; Dennefeld, C.; Blaner, W.S.; *et al.* The STRA6 receptor is essential for retinol-binding protein-induced insulin resistance but not for maintaining vitamin A homeostasis in tissues other than the eye. *J. Biol. Chem.* **2013**, *288*, 24528–24539.
60. Terra, R.; Wang, X.; Hu, Y.; Charpentier, T.; Lamarre, A.; Zhong, M.; Sun, H.; Mao, J.; Qi, S.; Luo, H.; *et al.* To investigate the necessity of STRA6 upregulation in T cells during T cell immune responses. *PLoS One* **2013**, *8*, e82808.

61. Duester, G.; Mic, F.A.; Molotkov, A. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. *Chem. Biol. Interact.* **2003**, *143–144*, 201–210.
62. Pares, X.; Farres, J.; Kedishvili, N.; Duester, G. Medium- and short-chain dehydrogenase/reductase gene and protein families: Medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism. *Cell. Mol. Life Sci.* **2008**, *65*, 3936–3949.
63. Farjo, K.M.; Moiseyev, G.; Nikolaeva, O.; Sandell, L.L.; Trainor, P.A.; Ma, J.X. RDH10 is the primary enzyme responsible for the first step of embryonic vitamin A metabolism and retinoic acid synthesis. *Dev. Biol.* **2011**, *357*, 347–355.
64. Napoli, J.L. Physiological insights into all-*trans*-retinoic acid biosynthesis. *Biochim. Biophys. Acta* **2012**, *1821*, 152–167.
65. Napoli, J.L. Retinoic acid biosynthesis and metabolism. *FASEB J.* **1996**, *10*, 993–1001.
66. Wolf, G. Cellular retinoic acid-binding protein II: A coactivator of the transactivation by the retinoic acid receptor complex, RAR.RXR. *Nutr. Rev.* **2000**, *58*, 151–153.
67. Kedishvili, N.Y. Enzymology of retinoic acid biosynthesis and degradation. *J. Lipid Res.* **2013**, *54*, 1744–1760.
68. Davidovici, B.B.; Tuzun, Y.; Wolf, R. Retinoid receptors. *Dermatol. Clin.* **2007**, *25*, 525–530.
69. Blomhoff, R.; Blomhoff, H.K. Overview of retinoid metabolism and function. *J. Neurobiol.* **2006**, *66*, 606–630.
70. Rochette-Egly, C.; Oulad-Abdelghani, M.; Staub, A.; Pfister, V.; Scheuer, I.; Chambon, P.; Gaub, M.P. Phosphorylation of the retinoic acid receptor- α by protein kinase, A. *Mol. Endocrinol.* **1995**, *9*, 860–871.
71. Rochette-Egly, C.; Adam, S.; Rossignol, M.; Egly, J.M.; Chambon, P. Stimulation of RAR α activation function AF-1 through binding to the general transcription factor TFIID and phosphorylation by CDK7. *Cell* **1997**, *90*, 97–107.
72. Delmotte, M.H.; Tahayato, A.; Formstecher, P.; Lefebvre, P. Serine 157, a retinoic acid receptor α residue phosphorylated by protein kinase C *in vitro*, is involved in RXR-RAR α heterodimerization and transcriptional activity. *J. Biol. Chem.* **1999**, *274*, 38225–38231.
73. Srinivas, H.; Xia, D.; Moore, N.L.; Uray, I.P.; Kim, H.; Ma, L.; Weigel, N.L.; Brown, P.H.; Kurie, J.M. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor α . *Biochem. J.* **2006**, *395*, 653–662.
74. Lee, H.Y.; Suh, Y.A.; Robinson, M.J.; Clifford, J.L.; Hong, W.K.; Woodgett, J.R.; Cobb, M.H.; Mangelsdorf, D.J.; Kurie, J.M. Stress pathway activation induces phosphorylation of retinoid X receptor. *J. Biol. Chem.* **2000**, *275*, 32193–32199.
75. Matsushima-Nishiwaki, R.; Okuno, M.; Adachi, S.; Sano, T.; Akita, K.; Moriwaki, H.; Friedman, S.L.; Kojima, S. Phosphorylation of retinoid X receptor α at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. *Cancer Res.* **2001**, *61*, 7675–7682.
76. Yamazaki, K.; Shimizu, M.; Okuno, M.; Matsushima-Nishiwaki, R.; Kanemura, N.; Araki, H.; Tsurumi, H.; Kojima, S.; Weinstein, I.B.; Moriwaki, H. Synergistic effects of RXR α and PPAR γ ligands to inhibit growth in human colon cancer cells—Phosphorylated RXR α is a critical target for colon cancer management. *Gut* **2007**, *56*, 1557–1563.

77. Kam, R.K.; Deng, Y.; Chen, Y.; Zhao, H. Retinoic acid synthesis and functions in early embryonic development. *Cell Biosci.* **2012**, *2*, doi:10.1186/2045-3701-2-11.
78. Das, B.C.; Thapa, P.; Karki, R.; Das, S.; Mahapatra, S.; Liu, T.C.; Torregroza, I.; Wallace, D.P.; Kambhampati, S.; van Veldhuizen, P.; *et al.* Retinoic acid signaling pathways in development and diseases. *Bioorg. Med. Chem.* **2014**, *22*, 673–683.
79. Connolly, R.M.; Nguyen, N.K.; Sukumar, S. Molecular pathways: Current role and future directions of the retinoic acid pathway in cancer prevention and treatment. *Clin. Cancer Res.* **2013**, *19*, 1651–1659.
80. Brun, P.J.; Yang, K.J.; Lee, S.A.; Yuen, J.J.; Blaner, W.S. Retinoids: Potent regulators of metabolism. *Biofactors* **2013**, *39*, 151–163.
81. Zhao, S.; Li, R.; Li, Y.; Chen, W.; Zhang, Y.; Chen, G. Roles of vitamin A status and retinoids in glucose and fatty acid metabolism. *Biochem. Cell Biol.* **2012**, *90*, 142–152.
82. Mongan, N.P.; Gudas, L.J. Diverse actions of retinoid receptors in cancer prevention and treatment. *Differentiation* **2007**, *75*, 853–870.
83. Park, H.; Green, M.H.; Shaffer, M.L. Association between serum retinol-binding protein 4 concentrations and clinical indices in subjects with type 2 diabetes: A meta-analysis. *J. Hum. Nutr. Diet.* **2012**, *25*, 300–310.
84. Basu, T.K.; Tze, W.J.; Leichter, J. Serum vitamin A and retinol-binding protein in patients with insulin-dependent diabetes mellitus. *Am. J. Clin. Nutr.* **1989**, *50*, 329–331.
85. Kiefer, F.W.; Orasanu, G.; Nallamshetty, S.; Brown, J.D.; Wang, H.; Luger, P.; Qi, N.R.; Burant, C.F.; Duester, G.; Plutzky, J. Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. *Endocrinology* **2012**, *153*, 3089–3099.
86. Wierdsma, N.J.; van Bokhorst-de van der Schueren, M.A.; Berkenpas, M.; Mulder, C.J.; van Bodegraven, A.A. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. *Nutrients* **2013**, *5*, 3975–3992.
87. Noy, N. The one-two punch: Retinoic acid suppresses obesity both by promoting energy expenditure and by inhibiting adipogenesis. *Adipocyte* **2013**, *2*, 184–187.
88. Bonet, M.L.; Ribot, J.; Palou, A. Lipid metabolism in mammalian tissues and its control by retinoic acid. *Biochim. Biophys. Acta* **2012**, *1821*, 177–189.
89. Amengual, J.; Ribot, J.; Bonet, M.L.; Palou, A. Retinoic acid treatment enhances lipid oxidation and inhibits lipid biosynthesis capacities in the liver of mice. *Cell. Physiol. Biochem.* **2010**, *25*, 657–666.
90. Basu, T.K.; Basualdo, C. Vitamin A homeostasis and diabetes mellitus. *Nutrition* **1997**, *13*, 804–806.
91. Basualdo, C.G.; Wein, E.E.; Basu, T.K. Vitamin A (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus. *J. Am. Coll. Nutr.* **1997**, *16*, 39–45.
92. Baena, R.M.; Campoy, C.; Bayes, R.; Blanca, E.; Fernandez, J.M.; Molina-Font, J.A. Vitamin A retinol binding protein and lipids in type 1 diabetes mellitus. *Eur. J. Clin. Nutr.* **2002**, *56*, 44–50.
93. Tuitoek, P.J.; Ziari, S.; Tsin, A.T.; Rajotte, R.V.; Suh, M.; Basu, T.K. Streptozotocin-induced diabetes in rats is associated with impaired metabolic availability of vitamin A (retinol). *Br. J. Nutr.* **1996**, *75*, 615–622.

94. Zunino, S.J.; Storms, D.H.; Stephensen, C.B. Diets rich in polyphenols and vitamin A inhibit the development of type I autoimmune diabetes in nonobese diabetic mice. *J. Nutr.* **2007**, *137*, 1216–1221.
95. Van, Y.H.; Lee, W.H.; Ortiz, S.; Lee, M.H.; Qin, H.J.; Liu, C.P. All-*trans* retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon- γ -producing T-cells without affecting Th17 cells. *Diabetes* **2009**, *58*, 146–155.
96. Cabre, A.; Lazaro, I.; Girona, J.; Manzanares, J.; Marimon, F.; Plana, N.; Heras, M.; Masana, L. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. *J. Intern. Med.* **2007**, *262*, 496–503.
97. Rocha, M.; Banuls, C.; Bellod, L.; Rovira-Llopis, S.; Morillas, C.; Sola, E.; Victor, V.M.; Hernandez-Mijares, A. Association of serum retinol binding protein 4 with atherogenic dyslipidemia in morbid obese patients. *PLoS One* **2013**, *8*, e78670.
98. Cho, Y.M.; Youn, B.S.; Lee, H.; Lee, N.; Min, S.S.; Kwak, S.H.; Lee, H.K.; Park, K.S. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. *Diabetes Care* **2006**, *29*, 2457–2461.
99. Yang, Q.; Graham, T.E.; Mody, N.; Preitner, F.; Peroni, O.D.; Zabolotny, J.M.; Kotani, K.; Quadro, L.; Kahn, B.B. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* **2005**, *436*, 356–362.
100. Manolescu, D.C.; Sima, A.; Bhat, P.V. All-*trans* retinoic acid lowers serum retinol-binding protein 4 concentrations and increases insulin sensitivity in diabetic mice. *J. Nutr.* **2010**, *140*, 311–316.
101. Berry, D.C.; Jin, H.; Majumdar, A.; Noy, N. Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 4340–4345.
102. Mukherjee, R.; Davies, P.J.; Crombie, D.L.; Bischoff, E.D.; Cesario, R.M.; Jow, L.; Hamann, L.G.; Boehm, M.F.; Mondon, C.E.; Nadzan, A.M.; *et al.* Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. *Nature* **1997**, *386*, 407–410.
103. Shen, Q.; Cline, G.W.; Shulman, G.I.; Leibowitz, M.D.; Davies, P.J. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. *J. Biol. Chem.* **2004**, *279*, 19721–19731.
104. Jeyakumar, S.M.; Vijaya Kumar, P.; Giridharan, N.V.; Vajreswari, A. Vitamin A improves insulin sensitivity by increasing insulin receptor phosphorylation through protein tyrosine phosphatase 1B regulation at early age in obese rats of WNIN/Ob strain. *Diabetes Obes. Metab.* **2011**, *13*, 955–958.
105. Mercader, J.; Ribot, J.; Murano, I.; Felipe, F.; Cinti, S.; Bonet, M.L.; Palou, A. Remodeling of white adipose tissue after retinoic acid administration in mice. *Endocrinology* **2006**, *147*, 5325–5332.
106. Amengual, J.; Ribot, J.; Bonet, M.L.; Palou, A. Retinoic acid treatment increases lipid oxidation capacity in skeletal muscle of mice. *Obesity (Silver Spring)* **2008**, *16*, 585–591.
107. Ribot, J.; Felipe, F.; Bonet, M.L.; Palou, A. Changes of adiposity in response to vitamin A status correlate with changes of PPAR γ 2 expression. *Obes. Res.* **2001**, *9*, 500–509.

108. Bonet, M.L.; Oliver, J.; Pico, C.; Felipe, F.; Ribot, J.; Cinti, S.; Palou, A. Opposite effects of feeding a vitamin A-deficient diet and retinoic acid treatment on brown adipose tissue uncoupling protein 1 (UCP1), UCP2 and leptin expression. *J. Endocrinol.* **2000**, *166*, 511–517.
109. Mercader, J.; Madsen, L.; Felipe, F.; Palou, A.; Kristiansen, K.; Bonet, M.L. All-*trans* retinoic acid increases oxidative metabolism in mature adipocytes. *Cell. Physiol. Biochem.* **2007**, *20*, 1061–1072.
110. Molotkov, A.; Duester, G. Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid. *J. Biol. Chem.* **2003**, *278*, 36085–36090.
111. Salazar, J.; Guardiola, M.; Ferre, R.; Coll, B.; Alonso-Villaverde, C.; Winklhofer-Roob, B.M.; Rock, E.; Fernandez-Ballart, J.D.; Civeira, F.; Pocovi, M.; *et al.* Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (*CRABP2*) with increased circulating low-density lipoprotein cholesterol. *Clin. Chem. Lab. Med.* **2007**, *45*, 615–620.
112. Kastner, P.; Messaddeq, N.; Mark, M.; Wendling, O.; Grondona, J.M.; Ward, S.; Ghyselinck, N.; Chambon, P. Vitamin A deficiency and mutations of, RXR α , RXR β and RAR α lead to early differentiation of embryonic ventricular cardiomyocytes. *Development* **1997**, *124*, 4749–4758.
113. Subbarayan, V.; Mark, M.; Messaddeq, N.; Rustin, P.; Chambon, P.; Kastner, P. RXR α overexpression in cardiomyocytes causes dilated cardiomyopathy but fails to rescue myocardial hypoplasia in RXR α -null fetuses. *J. Clin. Invest.* **2000**, *105*, 387–394.
114. Ryckebusch, L.; Wang, Z.; Bertrand, N.; Lin, S.C.; Chi, X.; Schwartz, R.; Zaffran, S.; Niederreither, K. Retinoic acid deficiency alters second heart field formation. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 2913–2918.
115. Zile, M.H. Vitamin A—Not for your eyes only: Requirement for heart formation begins early in embryogenesis. *Nutrients* **2010**, *2*, 532–550.
116. Noy, N. Between death and survival: Retinoic acid in regulation of apoptosis. *Annu. Rev. Nutr.* **2010**, *30*, 201–217.
117. Ahuja, H.S.; Szanto, A.; Nagy, L.; Davies, P.J. The retinoid X receptor and its ligands: Versatile regulators of metabolic function, cell differentiation and cell death. *J. Biol. Regul. Homeost. Agents* **2003**, *17*, 29–45.
118. Zhou, M.D.; Sucov, H.M.; Evans, R.M.; Chien, K.R. Retinoid-dependent pathways suppress myocardial cell hypertrophy. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 7391–7395.
119. Wu, J.; Garami, M.; Cheng, T.; Gardner, D.G. 1,25(OH) $_2$ vitamin D $_3$ and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. *J. Clin. Invest.* **1996**, *97*, 1577–1588.
120. Wang, H.J.; Zhu, Y.C.; Yao, T. Effects of all-*trans* retinoic acid on angiotensin II-induced myocyte hypertrophy. *J. Appl. Physiol.* **2002**, *92*, 2162–2168.
121. Palm-Leis, A.; Singh, U.S.; Herbelin, B.S.; Olsovsky, G.D.; Baker, K.M.; Pan, J. Mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases mediate the inhibitory effects of all-*trans* retinoic acid on the hypertrophic growth of cardiomyocytes. *J. Biol. Chem.* **2004**, *279*, 54905–54917.

122. He, Y.; Huang, Y.; Zhou, L.; Lu, L.M.; Zhu, Y.C.; Yao, T. All-*trans* retinoic acid inhibited angiotensin II-induced increase in cell growth and collagen secretion of neonatal cardiac fibroblasts. *Acta Pharmacol. Sin.* **2006**, *27*, 423–429.
123. Oliveira, L.C.; Azevedo, P.S.; Minicucci, M.E.; Rafacho, B.P.; Duarte, D.R.; Matsubara, L.S.; Matsubara, B.B.; Paiva, S.A.; Zornoff, L.A. Retinoic acid prevents ventricular remodelling induced by tobacco smoke exposure in rats. *Acta Cardiol.* **2011**, *66*, 3–7.
124. Lu, L.; Yao, T.; Zhu, Y.Z.; Huang, G.Y.; Cao, Y.X.; Zhu, Y.C. Chronic all-*trans* retinoic acid treatment prevents medial thickening of intramyocardial and intrarenal arteries in spontaneously hypertensive rats. *Am. J. Physiol. Heart Circ. Physiol.* **2003**, *285*, H1370–H1377.
125. Paiva, S.A.; Matsubara, L.S.; Matsubara, B.B.; Minicucci, M.F.; Azevedo, P.S.; Campana, A.O.; Zornoff, L.A. Retinoic acid supplementation attenuates ventricular remodeling after myocardial infarction in rats. *J. Nutr.* **2005**, *135*, 2326–2328.
126. Choudhary, R.; Palm-Leis, A.; Scott, R.C., III.; Guleria, R.S.; Rachut, E.; Baker, K.M.; Pan, J. All-*trans* retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the renin-angiotensin system. *Am. J. Physiol. Heart Circ. Physiol.* **2008**, *294*, H633–H644.
127. Mortuza, R.; Chakrabarti, S. Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy. *Heart Fail. Rev.* **2014**, *19*, 75–86.
128. Camps, M.; Castello, A.; Munoz, P.; Monfar, M.; Testar, X.; Palacin, M.; Zorzano, A. Effect of diabetes and fasting on GLUT-4 (muscle/fat) glucose-transporter expression in insulin-sensitive tissues. Heterogeneous response in heart, red and white muscle. *Biochem. J.* **1992**, *282*, 765–772.
129. Montessuit, C.; Lerch, R. Regulation and dysregulation of glucose transport in cardiomyocytes. *Biochim. Biophys. Acta* **2013**, *1833*, 848–856.
130. Coort, S.L.; Bonen, A.; van der Vusse, G.J.; Glatz, J.F.; Luiken, J.J. Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: Role of sarcolemmal substrate transporters. *Mol. Cell. Biochem.* **2007**, *299*, 5–18.
131. Young, M.E.; Guthrie, P.H.; Razeghi, P.; Leighton, B.; Abbasi, S.; Patil, S.; Youker, K.A.; Taegtmeier, H. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. *Diabetes* **2002**, *51*, 2587–2595.
132. Van de Weijer, T.; Schrauwen-Hinderling, V.B.; Schrauwen, P. Lipotoxicity in type 2 diabetic cardiomyopathy. *Cardiovasc. Res.* **2011**, *92*, 10–18.
133. Basu, R.; Oudit, G.Y.; Wang, X.; Zhang, L.; Ussher, J.R.; Lopaschuk, G.D.; Kassiri, Z. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. *Am. J. Physiol. Heart Circ. Physiol.* **2009**, *297*, H2096–H2108.
134. Pulinilkunnil, T.; Kienesberger, P.C.; Nagendran, J.; Waller, T.J.; Young, M.E.; Kershaw, E.E.; Korbitt, G.; Haemmerle, G.; Zechner, R.; Dyck, J.R. Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. *Diabetes* **2013**, *62*, 1464–1477.

135. Ouwens, D.M.; Diamant, M.; Fodor, M.; Habets, D.D.; Pelters, M.M.; El Hasnaoui, M.; Dang, Z.C.; van den Brom, C.E.; Vlasblom, R.; Rietdijk, A.; *et al.* Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. *Diabetologia* **2007**, *50*, 1938–1948.
136. Chiu, H.C.; Kovacs, A.; Blanton, R.M.; Han, X.; Courtois, M.; Weinheimer, C.J.; Yamada, K.A.; Brunet, S.; Xu, H.; Nerbonne, J.M.; *et al.* Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. *Circ. Res.* **2005**, *96*, 225–233.
137. Johansen, J.S.; Harris, A.K.; Rychly, D.J.; Ergul, A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. *Cardiovasc. Diabetol.* **2005**, *4*, doi:10.1186/1475-2840-4-5.
138. Ungvari, Z.; Gupte, S.A.; Recchia, F.A.; Batkai, S.; Pacher, P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. *Curr. Vasc. Pharmacol.* **2005**, *3*, 221–229.
139. Cai, L.; Kang, Y.J. Oxidative stress and diabetic cardiomyopathy: A brief review. *Cardiovasc. Toxicol.* **2001**, *1*, 181–193.
140. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; *et al.* Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* **2000**, *404*, 787–790.
141. Dirkx, E.; Schwenk, R.W.; Glatz, J.F.; Luiken, J.J.; van Eys, G.J. High fat diet induced diabetic cardiomyopathy. *Prostaglandins Leukot. Essent. Fatty Acids* **2011**, *85*, 219–225.
142. Drosatos, K.; Schulze, P.C. Cardiac lipotoxicity: Molecular pathways and therapeutic implications. *Curr. Heart Fail. Rep.* **2013**, *10*, 109–121.
143. Mukherjee, R.; Strasser, J.; Jow, L.; Hoener, P.; Paterniti, J.R., Jr.; Heyman, R.A. RXR agonists activate PPAR α -inducible genes, lower triglycerides, and raise HDL levels *in vivo*. *Arterioscler Thromb. Vasc. Biol.* **1998**, *18*, 272–276.
144. Aranda, A.; Pascual, A. Nuclear hormone receptors and gene expression. *Physiol. Rev.* **2001**, *81*, 1269–1304.
145. Schultz, J.R.; Tu, H.; Luk, A.; Repa, J.J.; Medina, J.C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D.J.; *et al.* Role of LXRs in control of lipogenesis. *Genes Dev.* **2000**, *14*, 2831–2838.
146. Poulsen, L.; Siersbaek, M.; Mandrup, S. PPARs: Fatty acid sensors controlling metabolism. *Semin. Cell Dev. Biol.* **2012**, *23*, 631–639.
147. Diamant, M.; Lamb, H.J.; Smit, J.W.; de Roos, A.; Heine, R.J. Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation. *Diabetologia* **2005**, *48*, 1669–1670.
148. Westermann, D.; Rutschow, S.; Jager, S.; Linderer, A.; Anker, S.; Riad, A.; Unger, T.; Schultheiss, H.P.; Pauschinger, M.; Tschope, C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: The role of angiotensin type 1 receptor antagonism. *Diabetes* **2007**, *56*, 641–646.
149. Palomer, X.; Salvado, L.; Barroso, E.; Vazquez-Carrera, M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. *Int. J. Cardiol.* **2013**, *168*, 3160–3172.

150. Gullestad, L.; Ueland, T.; Vinge, L.E.; Finsen, A.; Yndestad, A.; Aukrust, P. Inflammatory cytokines in heart failure: Mediators and markers. *Cardiology* **2012**, *122*, 23–35.
151. Paulus, W.J. Cytokines and heart failure. *Heart Fail. Monit.* **2000**, *1*, 50–56.
152. Wan, F.; Lenardo, M.J. The nuclear signaling of NF- κ B: Current knowledge, new insights, and future perspectives. *Cell Res.* **2010**, *20*, 24–33.
153. Valen, G.; Yan, Z.Q.; Hansson, G.K. Nuclear factor κ -B and the heart. *J. Am. Coll. Cardiol.* **2001**, *38*, 307–314.
154. Hofmann, M.A.; Schiekofer, S.; Isermann, B.; Kanitz, M.; Henkels, M.; Joswig, M.; Treusch, A.; Morcos, M.; Weiss, T.; Borcea, V.; *et al.* Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF- κ B. *Diabetologia* **1999**, *42*, 222–232.
155. Bierhaus, A.; Schiekofer, S.; Schwaninger, M.; Andrassy, M.; Humpert, P.M.; Chen, J.; Hong, M.; Luther, T.; Henle, T.; Kloting, I.; *et al.* Diabetes-associated sustained activation of the transcription factor nuclear factor- κ B. *Diabetes* **2001**, *50*, 2792–2808.
156. Granic, I.; Dolga, A.M.; Nijholt, I.M.; van Dijk, G.; Eisel, U.L. Inflammation and NF- κ B in Alzheimer's disease and diabetes. *J. Alzheimers Dis.* **2009**, *16*, 809–821.
157. Baker, R.G.; Hayden, M.S.; Ghosh, S. NF- κ B, inflammation, and metabolic disease. *Cell Metab.* **2011**, *13*, 11–22.
158. Chen, S.; Khan, Z.A.; Cukiernik, M.; Chakrabarti, S. Differential activation of NF- κ B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. *Am. J. Physiol. Endocrinol. Metab.* **2003**, *284*, E1089–E1097.
159. Lorenzo, O.; Picatoste, B.; Ares-Carrasco, S.; Ramirez, E.; Egido, J.; Tunon, J. Potential role of nuclear factor κ B in diabetic cardiomyopathy. *Mediat. Inflamm.* **2011**, *2011*, doi:10.1155/2011/652097.
160. Xu, J.; Chavis, J.A.; Racke, M.K.; Drew, P.D. Peroxisome proliferator-activated receptor- α and retinoid, X receptor agonists inhibit inflammatory responses of astrocytes. *J. Neuroimmunol.* **2006**, *176*, 95–105.
161. Lalloyer, F.; Fievet, C.; Lestavel, S.; Torpier, G.; van der Veen, J.; Touche, V.; Bultel, S.; Yous, S.; Kuipers, F.; Paumelle, R.; *et al.* The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. *Arterioscler Thromb. Vasc. Biol.* **2006**, *26*, 2731–2737.
162. Villamor, E.; Fawzi, W.W. Effects of vitamin a supplementation on immune responses and correlation with clinical outcomes. *Clin. Microbiol. Rev.* **2005**, *18*, 446–464.
163. Long, K.Z.; Garcia, C.; Ko, G.; Santos, J.I.; Al Mamun, A.; Rosado, J.L.; DuPont, H.L.; Nathakumar, N. Vitamin A modifies the intestinal chemokine and cytokine responses to norovirus infection in Mexican children. *J. Nutr.* **2011**, *141*, 957–963.
164. Reifen, R.; Nur, T.; Ghebermeskel, K.; Zaiger, G.; Urizky, R.; Pines, M. Vitamin A deficiency exacerbates inflammation in a rat model of colitis through activation of nuclear factor- κ B and collagen formation. *J. Nutr.* **2002**, *132*, 2743–2747.
165. Austenaa, L.M.; Carlsen, H.; Ertesvag, A.; Alexander, G.; Blomhoff, H.K.; Blomhoff, R. Vitamin A status significantly alters nuclear factor- κ B activity assessed by *in vivo* imaging. *FASEB J.* **2004**, *18*, 1255–1257.

166. Gatica, L.; Alvarez, S.; Gomez, N.; Zago, M.P.; Oteiza, P.; Oliveros, L.; Gimenez, M.S. Vitamin A deficiency induces prooxidant environment and inflammation in rat aorta. *Free Radic Res.* **2005**, *39*, 621–628.
167. Ning, R.B.; Zhu, J.; Chai, D.J.; Xu, C.S.; Xie, H.; Lin, X.Y.; Zeng, J.Z.; Lin, J.X. RXR agonists inhibit high glucose-induced upregulation of inflammation by suppressing activation of the NADPH oxidase-nuclear factor- κ B pathway in human endothelial cells. *Genet Mol. Res.* **2013**, *12*, 6692–6707.
168. Beitelshees, A.L.; Zineh, I. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: Implications in heart failure management. *Heart Fail. Rev.* **2010**, *15*, 209–217.
169. Lang, C.C.; Struthers, A.D. Targeting the renin-angiotensin-aldosterone system in heart failure. *Nat. Rev. Cardiol.* **2013**, *10*, 125–134.
170. Hershon, K.S. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. *Endocr. Pract.* **2011**, *17*, 430–440.
171. Frustaci, A.; Kajstura, J.; Chimenti, C.; Jakoniuk, I.; Leri, A.; Maseri, A.; Nadal-Ginard, B.; Anversa, P. Myocardial cell death in human diabetes. *Circ. Res.* **2000**, *87*, 1123–1132.
172. Fiordaliso, F.; Li, B.; Latini, R.; Sonnenblick, E.H.; Anversa, P.; Leri, A.; Kajstura, J. Myocyte death in streptozotocin-induced diabetes in rats is angiotensin, II-dependent. *Lab. Invest.* **2000**, *80*, 513–527.
173. Brown, L.; Wall, D.; Marchant, C.; Sernia, C. Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. *J. Endocrinol.* **1997**, *154*, 355–362.
174. Fiordaliso, F.; Leri, A.; Cesselli, D.; Limana, F.; Safai, B.; Nadal-Ginard, B.; Anversa, P.; Kajstura, J. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. *Diabetes* **2001**, *50*, 2363–2375.
175. Sechi, L.A.; Griffin, C.A.; Schambelan, M. The cardiac renin-angiotensin system in STZ-induced diabetes. *Diabetes* **1994**, *43*, 1180–1184.
176. Singh, V.P.; Le, B.; Khode, R.; Baker, K.M.; Kumar, R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. *Diabetes* **2008**, *57*, 3297–3306.
177. Dechow, C.; Morath, C.; Peters, J.; Lehrke, I.; Waldherr, R.; Haxsen, V.; Ritz, E.; Wagner, J. Effects of all-*trans* retinoic acid on renin-angiotensin system in rats with experimental nephritis. *Am. J. Physiol. Renal Physiol.* **2001**, *281*, F909–F919.
178. Takeda, K.; Ichiki, T.; Funakoshi, Y.; Ito, K.; Takeshita, A. Downregulation of angiotensin II type 1 receptor by all-*trans* retinoic acid in vascular smooth muscle cells. *Hypertension* **2000**, *35*, 297–302.
179. Zhong, J.C.; Huang, D.Y.; Yang, Y.M.; Li, Y.F.; Liu, G.F.; Song, X.H.; Du, K. Upregulation of angiotensin-converting enzyme 2 by all-*trans* retinoic acid in spontaneously hypertensive rats. *Hypertension* **2004**, *44*, 907–912.
180. Haxsen, V.; Adam-Stitah, S.; Ritz, E.; Wagner, J. Retinoids inhibit the actions of angiotensin II on vascular smooth muscle cells. *Circ. Res.* **2001**, *88*, 637–644.

181. Zhong, J.C.; Huang, D.Y.; Liu, G.F.; Jin, H.Y.; Yang, Y.M.; Li, Y.F.; Song, X.H.; Du, K. Effects of all-*trans* retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. *Cardiovasc. Res.* **2005**, *65*, 743–750.
182. Leid, M.; Kastner, P.; Chambon, P. Multiplicity generates diversity in the retinoic acid signalling pathways. *Trends Biochem. Sci.* **1992**, *17*, 427–433.
183. Lufkin, T.; Lohnes, D.; Mark, M.; Dierich, A.; Gorry, P.; Gaub, M.P.; LeMeur, M.; Chambon, P. High postnatal lethality and testis degeneration in retinoic acid receptor α mutant mice. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 7225–7229.
184. Sucov, H.M.; Dyson, E.; Gumeringer, C.L.; Price, J.; Chien, K.R.; Evans, R.M. RXR α mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. *Genes Dev.* **1994**, *8*, 1007–1018.
185. Osorio, J.C.; Stanley, W.C.; Linke, A.; Castellari, M.; Diep, Q.N.; Panchal, A.R.; Hintze, T.H.; Lopaschuk, G.D.; Recchia, F.A. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor- α in pacing-induced heart failure. *Circulation* **2002**, *106*, 606–612.
186. Feingold, K.; Kim, M.S.; Shigenaga, J.; Moser, A.; Grunfeld, C. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. *Am. J. Physiol. Endocrinol. Metab.* **2004**, *286*, E201–E207.
187. Singh, A.B.; Guleria, R.S.; Nizamutdinova, I.T.; Baker, K.M.; Pan, J. High Glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling. *J. Cell. Physiol.* **2012**, *227*, 2632–2644.
188. Zhu, S.; Guleria, G.S.; Thomas, C.M.; Kumar, R.; Roth, A.; Baker, K.M.; Pan, J. Cardiomyocyte-specific deletion of RAR α and RXR α induces diastolic heart failure. *Circulation Res.*, in preparation, 2014.
189. Bastien, J.; Rochette-Egly, C. Nuclear retinoid receptors and the transcription of retinoid-target genes. *Gene* **2004**, *328*, 1–16.
190. Zassadowski, F.; Rochette-Egly, C.; Chomienne, C.; Cassinat, B. Regulation of the transcriptional activity of nuclear receptors by the, MEK/ERK1/2 pathway. *Cell. Signal.* **2012**, *24*, 2369–2377.
191. Macoritto, M.; Nguyen-Yamamoto, L.; Huang, D.C.; Samuel, S.; Yang, X.F.; Wang, T.T.; White, J.H.; Kremer, R. Phosphorylation of the human retinoid X receptor α at serine 260 impairs coactivator(s) recruitment and induces hormone resistance to multiple ligands. *J. Biol. Chem.* **2008**, *283*, 4943–4956.
192. Rochette-Egly, C. Nuclear receptors: Integration of multiple signalling pathways through phosphorylation. *Cell. Signal.* **2003**, *15*, 355–366.
193. Solomon, C.; White, J.H.; Kremer, R. Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin, D₃-dependent signal transduction by phosphorylating human retinoid X receptor α . *J. Clin. Invest.* **1999**, *103*, 1729–1735.
194. Adam-Stitah, S.; Penna, L.; Chambon, P.; Rochette-Egly, C. Hyperphosphorylation of the retinoid X receptor α by activated c-Jun, NH₂-terminal kinases. *J. Biol. Chem.* **1999**, *274*, 18932–18941.

195. Hoshikawa, Y.; Kanki, K.; Ashla, A.A.; Arakaki, Y.; Azumi, J.; Yasui, T.; Tezuka, Y.; Matsumi, Y.; Tsuchiya, H.; Kurimasa, A.; *et al.* c-Jun N-terminal kinase activation by oxidative stress suppresses retinoid signaling through proteasomal degradation of retinoic acid receptor α protein in hepatic cells. *Cancer Sci.* **2011**, *102*, 934–941.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).